The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action

Pharmacogenetics and Genomics

Volumn 21, Issue 11, 2011, Pages 741-750

  Hafner, Mateja ^a   Juvan, Peter ^a   Rezen, Tadeja ^a   Monostory, Katalin ^b   Pascussi, Jean Marc ^c,d   Rozman, Damjana ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b CHEMICAL RESEARCH CENTER   (Hungary)

^c INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^d UNIV MONTPELLIER   (France)

Author keywords

atorvastatin; constitutive androstan receptor; human liver; rosuvastatin; transcriptome

Indexed keywords

ACETYL COENZYME A; ADIPONECTIN; ADIPONECTIN RECEPTOR 2; ANDROSTANE DERIVATIVE; ATORVASTATIN; BILE ACID; CHOLESTEROL; CHOLESTEROL ESTER; COMPLEMENTARY DNA; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PREGNANE X RECEPTOR; RIFAMPICIN; ROSUVASTATIN; TRANSCRIPTOME;

ARTICLE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; FATTY LIVER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

CELLS, CULTURED; CHOLESTEROL; ENERGY METABOLISM; FLUOROBENZENES; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HEPATOCYTES; HEPTANOIC ACIDS; HOMEOSTASIS; HUMANS; MEMBRANE TRANSPORT PROTEINS; METABOLIC NETWORKS AND PATHWAYS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYRIMIDINES; PYRROLES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; REPRODUCIBILITY OF RESULTS; SULFONAMIDES; TRANSCRIPTOME;

EID: 80054966640     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834a5585     Document Type: Article

References (60)

1. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19:26-37.
2. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80:565-581.
3. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 2003; 4:9-14.
4. Poli A. Atorvastatin: pharmacological characteristics and lipid-lowering effects. Drugs 2007; 67 (Suppl 1):3-15.
5. Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T,Wolzt M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001; 85:47-51.
6. Wierzbicki AS, Mikhailidis DP. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int J Cardiol 2002; 84:53-57.
7. De Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin- JUPITER controversy: a critical reappraisal. Arch Intern Med 2010; 170:1032-1036.
8. Rozman D, Monostory K. Perspectives of the non-statin hypolipidemic agents. Pharmacol Ther 2010; 127:19-40.
9. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007; 49:1753-1762.
10. Jacobson TA. Toward 'Pain-Free' statin prescribing: Clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008; 83:687-700.
11. Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 2009; 11:272-278.
12. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007; 50:409-418.
13. Zarowitz BJ. Are statins safe? Geriatr Nurs 2007; 28:212-217.
14. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102:1016-1023.
15. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30:795-804.
16. Bayliss M, Somers G. Isolation and culture of human hepatocytes. Methods Mol Med 2005; 107:249-267.
17. Ferrini JB, Ourlin JC, Pichard L, Fabre G, Maurel P. Human hepatocyte culture. Methods Mol Biol 1998; 107:341-352.
18. Rezen T, Juvan P, Fon Tacer K, Kuzman D, Roth A, Pompon D, et al. The Sterolgene v0 cDNA microarray: a systemic approach to studies of cholesterol homeostasis and drug metabolism. BMC Genomics 2008; 9:76.
19. Rezen T, Tamasi V, Lovgren-Sandblom A, Bjorkhem I, Meyer UA, Rozman D. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers. BMC Genomics 2009; 10:384.
20. Simoncic M, Rezen T, Juvan P, Rozman D, Fazarinc G, Fievet C, et al. Obesity resistant mechanisms in the Lean polygenic mouse model as indicated by liver transcriptome and expression of selected genes in skeletal muscle. BMC Genomics 2011; 12:96.
21. Kobayashi K, Yamanaka Y, Iwazaki N, Nakajo I, Hosokawa M, Negishi M, et al. Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos 2005; 33:924-929.
22. Kocarek TA, Dahn MS, Cai H, Strom SC, Mercer-Haines NA. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab Dispos 2002; 30:1400-1405.
23. Yuen T, Wurmbach E, Pfeffer RL, Ebersole BJ, Sealfon SC. Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res 2002; 30:e48.
24. Wang YL, Barbacioru C, Hyland F, Xiao WM, Hunkapiller KL, Blake J, et al. Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics 2006; 7:7-59.
25. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 2007; 23:3251-3253.
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102:15545-15550.
27. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89:331-340.
28. Wada T, Gao J, PXR Xie W. and CAR in energy metabolism. Trends Endocrinol Metab 2009; 20:273-279.
29. Konno Y, Negishi M, Kodama S. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab Pharmacokinet 2008; 23:8-13.
30. Lada AT, Davis M, Kent C, Chapman J, Tomoda H, Omura S, et al. Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cellbased fluorescence assay: individual ACAT uniqueness. J Lipid Res 2004; 45:378-386.
31. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32:1924-1929.
32. Ridker PM, Friedewald VE, Davidson MH, Willerson JT, Roberts WC. The editor's roundtable: the JUPITER trial - initial results and clinical implications. Am J Cardiol 2009; 103:1417-1425.
33. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R, et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 2002; 110:489-500.
34. Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, Goldstein JL. Sterolregulated transport of SREBPs from endoplasmic reticulum to golgi: oxysterols block transport by binding to Insig. Proc Natl Acad Sci USA 2007; 104:6511-6518.
35. Sever N, Song BL, Yabe D, Goldstein JL, Brown MS, DeBose-Boyd RA. Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3- methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. J Biol Chem 2003; 278:52479-52490.
36. Horvat S, McWhir J, Rozman D. Defects in cholesterol synthesis genes in mouse and in humans: lessons for drug development and safer treatments. Drug Metab Rev 2011; 43:69-90.
37. Monostory K, Pascussi JM, Szabo P, Temesvari M, Kohalmy K, Acimovic J, et al. Drug interaction potential of 2-[(3,4-dichlorophenethyl)(propyl)amino]- 1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterollowering agent. Drug Metab Dispos 2009; 37:375-385.
38. Ridker PM. The JUPITER trial: results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes 2009; 2:279-285.
39. Stoffel M, Duncan SA. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A 1997; 94:13209-13214.
40. Gorovits N, Cui L, Busik JV, Ranalletta M, Hauguel de-Mouzon S, Charron MJ. Regulation of hepatic GLUT8 expression in normal and diabetic models. Endocrinology 2003; 144:1703-1711.
41. Evans SA, Doblado M, Chi MM, Corbett JA, Moley KH. Facilitative glucose transporter 9 expression affects glucose sensing in pancreatic beta-cells. Endocrinology 2009; 150:5302-5310.
42. Gelissen IC, Harris M, Rye KA, Quinn C, Brown AJ, Kockx M, et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 2006; 26:534-540.
43. Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch 2007; 453:601-610.
44. LaFave LT, Augustin LB, Mariash CN. S14: insights from knockout mice. Endocrinology 2006; 147:4044-4047.
45. Breuker C, Moreau A, Lakhal L, Tamasi V, Parmentier Y, Meyer U, et al. Hepatic expression of thyroid hormone-responsive spot 14 protein is regulated by constitutive androstane receptor (NR1I3). Endocrinology 2010; 151:1653-1661.
46. Campbell MC, Anderson GW, Mariash CN. Human spot 14 glucose and thyroid hormone response: characterization and thyroid hormone response element identification. Endocrinology 2003; 144:5242-5248.
47. Feng X, Jiang Y, Meltzer P, Yen PM. Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol 2000; 14:947-955.
48. Oppenheimer JH, Kinlaw WB, Wong NC, Schwartz HL, Mariash CN. Regulation of gene S-14 by triiodothyronine in liver. Horm Metab Res Suppl 1987; 17:1-5.
49. Moreau A, Teruel C, Beylot M, Albalea V, Tamasi V, Umbdenstock T, et al. A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology 2009; 49:2068-2079.
50. Pawar A, Botolin D, Mangelsdorf DJ, Jump DB. The role of liver X receptoralpha in the fatty acid regulation of hepatic gene expression. J Biol Chem 2003; 278:40736-40743.
51. Dentin R, Pegorier JP, Benhamed F, Foufelle F, Ferre P, Fauveau V, et al. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem 2004; 279:20314-20326.
52. Ishii S, Iizuka K, Miller BC, Uyeda K. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci USA 2004; 101:15597-15602.
53. Zhu Q, Anderson GW, Mucha GT, Parks EJ, Metkowski JK, Mariash CN. The Spot 14 protein is required for de novo lipid synthesis in the lactating mammary gland. Endocrinology 2005; 146:3343-3350.
54. Colbert CL, Kim CW, Moon YA, Henry L, Palnitkar M, McKean WB, et al. Crystal structure of Spot 14, a modulator of fatty acid synthesis. Proc Natl Acad Sci USA 2010; 107:18820-18825.
55. Aipoalani DL, O'Callaghan BL, Mashek DG, Mariash CN, Towle HC. Overlapping roles of the glucose-responsive genes, S14 and S14R, in hepatic lipogenesis. Endocrinology 2010; 151:2071-2077.
56. Brookheart RT, Michel CI, Schaffer JE. As a matter of fat. Cell Metab 2009; 10:9-12.
57. Wakil SJ, Abu-Elheiga LA. Fatty acid metabolism: target for metabolic syndrome. J Lipid Res 2009; Suppl: S138-143:50.
58. Anderson GW, Zhu Q, Metkowski J, Stack MJ, Gopinath S, Mariash CN. The Thrsp null mouse (Thrsp(tm1cnm)) and diet-induced obesity. Mol Cell Endocrinol 2009; 302:99-107.
59. Cao ZP,Wang SZ,Wang QG,Wang YX, Li H. Association of Spot14alpha gene polymorphisms with body weight in the chicken. Poult Sci 2007; 86:1873-1880.
60. Wang HB, Li H,Wang QG, Zhang XY,Wang SZ,Wang YX, et al. Profiling of chicken adipose tissue gene expression by genome array. BMC Genomics 2007; 8:193.